Skip to Content
Stanford Medicine Dermatology

Stanford Medicine

Explore Stanford Medicine

  • Health Care
    • Find a doctor

    • Adult-care doctor
    • Pediatrician or pediatric specialist
    • Obstetrician
    • Clinics & Services

    • Adult care
    • Pediatric care
    • Obstetrics
    • Clinical trials
    • Locations

    • Stanford Health Care
    • Stanford Children's Health
    • Emergency Department
    • Dial 911 in the event of a medical emergency

    Explore Health Care

    Learn how we are healing patients through science & compassion

    Back
  • Research
    • Basic science departments
    • Clinical science departments
    • Institutes
    • Research centers
    • See full directory
    • Research Resources

    • Research administration
    • Academic profiles
    • Clinical trials
    • Funding opportunities
    • See all
    • Professional Training

    • Postdoctoral scholars
    • Clinical research fellows

    Research News

    Neuroscientist Michelle Monje awarded MacArthur 'genius grant'

    Neuroscientist Michelle Monje awarded MacArthur 'genius grant'

    Explore Research

    Learn how we are fueling innovation

    Back
  • Education
    • MD program
    • PA Programs
    • PhD programs
    • Masters programs
    • Continuing Medical Education
    • Postdoctoral scholars
    • Residencies & fellowships
    • High School & Undergraduate Programs
    • See all
    • Education Resources

    • Academic profiles
    • School Administration
    • Basic science departments
    • Clinical science departments
    • Alumni services
    • Faculty resources
    • Diversity programs
    • Lane Library
    • Student resources

    Education News

    Alice L. Walton School of Medicine and Stanford Medicine host AI conference on community health

    Alice L. Walton School of Medicine and Stanford Medicine host AI conference on community health

    Explore Education

    Learn how we empower tomorrow's leaders

    Back
  • Give

    Support Stanford Medicine

    • Support teaching, research, and patient care.

    • Ways to give
    • Why giving matters
    • Make a gift online

    Support Children's Health

    • Support Lucile Packard Children's Hospital Stanford and child and maternal health

    • Ways to give
    • How your gift helps
    • Make an online gift
    Back
  • About
    • About us
    • News
    • Contacts
    • Maps & directions
    • Leadership
    • Vision
    • Diversity
    • Global health
    • Community engagement
    • Events
    • How you can help

    Stanford School of Medicine

    Stanford Health Care

    Stanford Children's Health

    Back
  • Site Search
  • Faculty

    Faculty

    • All Affiliated Faculty
    • Open Faculty Positions
  • Education

    Education

    • Residency

      Residency

      • Message from Program Directors
      • Residency Program Leadership
      • Research and Elective Opportunities
      • Subspecialties
      • Curriculum
      • Residents
      • Resident Life
      • Resident Wellness
      • Application Process
      • Resources
      • Global Health
      • Clinical Sites
      • Salary & Benefits
    • Medical Students
    • Fellowship

      Fellowship

      • Post-Doctoral Research Fellowship
      • Peds Research Fellowship
      • Melanoma-focused Research Fellowship
    • Visiting Rotations & Observerships
    • Grand Rounds

      Grand Rounds

      • Information for Patients
      • Information for Doctors
      • Directions
    • Rodan + Fields Lecture
    • COVID as a Catalyst Webinar
    • Marvin Karasek Lecture
  • Research

    Research

    • Stanford EB Research

      Stanford EB Research

      • Current Studies

        Current Studies

        • Genetic Testing for DEB
        • Serlopitant for Itch in EB
        • Characteristics of RDEB Patients
        • EB 101 for RDEB
        • Intravenous C7 for RDEB
        • Injected Gene Therapy for RDEB
        • Exon Skipping Therapy
        • EBCRC
        • RDEB Wound Natural History
        • Stanford and UMCG Cannabinoid Survey
        • Drug Repurposing
      • Prior Clinical Studies
      • Pre-Clinical Studies to Date
      • Meet the Clinical Research Team
      • Stanford EB Publications
      • In the Press
    • Clinical Trials
    • Skin Cancer Brochure
    • Epithelial Biology Program
    • Stanford EB Research

      Stanford EB Research

      • Current Studies

        Current Studies

        • Serlopitant for Itch in EB
        • Characteristics of RDEB Patients
        • EB 101 for RDEB
        • Intravenous C7 for RDEB
        • Topical Gene Therapy for RDEB
        • Injected Gene Therapy for RDEB
        • Exon Skipping Therapy
        • EBCRC
        • RDEB Wound Natural History
        • Stanford and UMCG Cannabinoid Survey
        • Drug Repurposing
      • Prior Clinical Studies
      • Pre-Clinical Studies to Date
      • Meet the Clinical Research Team
      • Stanford EB Publications
      • In the Press
    • Stanford Skin Innovation and Interventional Research Group
    • Translational AI in Dermatology (TRAIND)
  • Resources

    Resources

    • Department History
    • Photo Instruction for Video Visits
    • Epithelial Biology Program
    • Genetic Skin Disease Center

      Genetic Skin Disease Center

      • Epidermolysis Bullosa Clinic

        Epidermolysis Bullosa Clinic

        • EB FAQs
        • EB Clinic Visits
        • EB Wound Care Videos
        • EB Resources
        • EB People
      • Our Team
      • Clinic Appointments and Referrals
      • Support Our Research
      • Contact Us
    • In The Spotlight Archive
    • Related Links
    • Clinical Schedules
    • Newsletter
    • Resident On-Call Schedule
  • Patient Care

    Patient Care

    • All Clinics
    • Directions to SMOC
    • Subspecialties
  • Contact

    Contact

    • Administrative Staff
  • SUPPORT

Clinical Trials Unit

Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit. 

The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications.  The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments.  New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies. 

Skin Aging Studies

We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.

Nonmelanoma Skin Cancer

Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.

Acne Rosecea

This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.

Contact

For more information, please email dermtrials@stanford.edu

Featured Clinical Trials

No trials match your search ""

Psoriasis Clinical Trials

  • Prostate Active Surveillance Study

    The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.

    Investigators

    • James D. Brooks
    • Harcharan Gill
    • Benjamin I. Chung
    Now accepting new patients View Details
  • Pediatric PET/MR Image Registry

    The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.

    Investigators

    • Kip E. Guja, MD PhD
    • Heike Daldrup-Link
    Now accepting new patients View Details
  • Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia

    Recent findings suggest that sleep disruption may contribute to the generation and maintenance of neuropsychiatric symptoms including anxiety, depression, agitation, irritation, and apathy while treating sleep disruption reduces these symptoms. Impairments in the neural systems that support emotion regulation may represent one causal mechanism mediating the relationship between sleep and emotional distress. However, this model has not yet been formally tested within a sample of individuals with or at risk for developing Alzheimer's Disease (AD)

    This proposal aims to test a mechanistic model in which sleep disturbance contributes to neuropsychiatric symptoms through impairments in fronto-limbic emotion regulation function in a sample of individuals at risk for developing, or at an early stage of AD.

    This study seeks to delineate the causal association between sleep disruption, fronto-limbic emotion regulation brain function, and neuropsychiatric symptoms. These aims will be achieved through a mechanistic, randomized 2-arm controlled trial design. 150 adults experiencing sleep disturbances and who also have cognitive impairment with the presence of at least mild neuropsychiatric symptoms will be randomized to receive either a sleep manipulation (Cognitive Behavioral Therapy for Insomnia CBT-I; n=75) or an active control (n=75). CBT-I improves sleep patterns through a combination of sleep restriction, stimulus control, mindfulness training, cognitive therapy targeting dysfunctional beliefs about sleep, and sleep hygiene education. Neuropsychiatric symptoms, fronto-limbic functioning, and sleep disruption will be assessed at baseline and at the end of the sleep manipulation through functional Magnetic Resonance Imaging (fMRI), clinical interviews, PSG recordings, and self-report questionnaires. Neuropsychiatric symptoms (anxiety and depression) and sleep disturbance (actigraphy, Insomnia Severity Index, and sleep diaries) will be assayed at baseline and each week throughout the sleep manipulation to assess week-to-week changes following an increasing number of CBT-I sessions. Wristwatch actigraphy will be acquired from baseline to the end of the sleep manipulation at week 11. Neuropsychiatric symptoms and sleep will be assessed again at six months post-manipulation.

    Investigator

    • Andrea Goldstein-Piekarski
    Now accepting new patients View Details
  • Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

    The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

    Investigators

    • Harlan Pinto
    • Billy W Loo, Jr, MD PhD FASTRO FACR
    • Quynh-Thu Le, MD, FACR, FASTRO
    • John B. Sunwoo, MD
    Now accepting new patients View Details
  • Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression

    The goal of this clinical trial is to compare ketamine to a placebo when given as a single infusion during IV sedation in adults with chronic pain and depression. We do not know whether ketamine will be more effective than placebo under these circumstances.

    This study aims to:

    * Evaluate whether placebo is non-inferior to ketamine in treating chronic pain and depression, when delivered under propofol sedation* Confirm that propofol sedation is a safe way to keep participants blinded to treatment* Assess patients' comfort with the sedation process to improve future studies* Explore whether patient expectations affects their pain and depression

    Participants will:

    * Need to qualify for the study based on stringent medical criteria* Undergo sedation with propofol* Randomly receive either a ketamine or a placebo (saline) infusion during sedation* Complete several study assessments over 5-7 weeks

    Investigator

    • Theresa Lii, M.D., M.S.
    Now accepting new patients View Details
  • Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

    This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

    Investigator

    • Natalie Shaubie Lui
    Now accepting new patients View Details
  • Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

    This is a protocol for prescreening of participants who would like to be in clinical studies in our Center at Stanford.

    Investigator

    • Sayantani Sindher
    Now accepting new patients View Details
  • Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

    Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.

    Now accepting new patients View Details
  • Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy.

    The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.

    Investigator

    • Jay Michael S. Balagtas
    Now accepting new patients View Details
  • Parent Intervention for Psychiatrically-Hospitalized Youth

    The purpose of the present study is to conduct a pilot randomized clinical trial (RCT) of a parent coaching intervention for parents of youth hospitalized for suicidal ideation, suicide attempt(s), or non-suicidal self-injury. Parents will receive either the parent coaching intervention (which includes safety planning and behavioral parenting skills training with a clinician and assistance with linkage to follow-up care by a case manager) or treatment as usual (TAU) for the inpatient unit. The long-term goal of the research is to determine if augmenting standard inpatient treatment with additional parenting intervention improves youth treatment response on suicide-related outcomes (i.e., suicidal ideation, non-suicidal self-injury, and suicide attempts). The goal of this pilot RCT is to collect preliminary data needed for a larger RCT, including feasibility, acceptability, safety, tolerability, engagement of the presumed mechanism of change (changes in parent emotions and behaviors), and signal detection of any changes in youth suicide-related outcomes.

    Investigator

    • Michele Berk, Ph.D.
    Now accepting new patients View Details
  • The GAstric Precancerous Conditions Study

    Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) are precancerous changes to the stomach mucosa which increases risk for subsequent gastric cancer.

    The Gastric Precancerous Conditions Study (GAPS) is an observational study of patients at elevated risk for gastric cancer. Investigators seek to recruit patients from endoscopy unit of Stanford Health Care, a large academic network of hospitals and clinics serving Northern California. Investigators will recruit patients who are both symptomatic (e.g. dyspepsia) and asymptomatic (e.g. referred for screening), and individuals both with known precursor lesions (such as intestinal metaplasia) or at high risk for carrying precursor lesions. A component of the study is long-term follow-up of individuals with gastric precursors. This is to understand their risk factors for histologic progression and regression. During both index and subsequent endoscopies, the study team will collect biospecimens (e.g. blood, saliva, gastric tissue).

    Investigators

    • Robert Huang
    • Joo Ha Hwang, MD, PhD
    Now accepting new patients View Details
  • Pediatric Prehospital Airway Resuscitation Trial

    This study is a Phase 3, multi-center, Bayesian Adaptive Sequential Platform Trial testing the effectiveness of different prehospital airway management strategies in the care of critically ill children. Emergency Medical Services (EMS) agencies affiliated with the Pediatric Emergency Care Applied Research Network (PECARN) will participate in the trial. The study interventions are strategies of prehospital airway management: \[BVM-only\], \[BVM followed by SGA\] and \[BVM followed by ETI\]. The primary outcome is 30-day ICU-free survival. The trial will be organized and executed in two successive stages. In Stage I of the trial, EMS personnel will alternate between two strategies: \[BVM-only\] or \[BVM followed by SGA\]. The \[winner of Stage I\] will advance to Stage II based upon results of Bayesian interim analyses. In Stage II of the trial, EMS personnel will alternate between \[BVM followed by ETI\] vs. \[Winner of Stage I\].

    Investigator

    • Manish I. Shah, MD, MS
    Now accepting new patients View Details
  • Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

    The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.

    Investigator

    • David Epstein
    Now accepting new patients View Details
  • Roadmap to Parenthood: Testing the Efficacy of a Decision Aid and Planning Tool for Family Building After Cancer

    This study will test a decision support intervention that consists of a web-based 'decision aid and planning tool' for family building after cancer in a randomized controlled trial.

    Investigator

    • Catherine Benedict, PhD
    Now accepting new patients View Details
  • SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

    SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

    The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of continuing on treatment for \>24 weeks.

    Investigator

    • Joyce Teng, MD, PhD
    Now accepting new patients View Details
  • Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

    The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.

    Now accepting new patients View Details
  • Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility

    The aims of this protocol are: to collect and store diseased and normal tissue and body fluid samples from new and returning patients at St. Jude Children's Research Hospital (SJCRH), affiliated sites and collaborating institutions; to collect and store samples from relatives of SJCRH patients; to collect and store retrospective and prospective pertinent corresponding clinical and laboratory data on disease characterization, treatment, and outcome; and to serve as a source of human biological samples and corresponding laboratory and clinical data.

    Investigator

    • Norman J. Lacayo, MD
    Now accepting new patients View Details
  • Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation

    The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.

    Investigator

    • Alexander C. Perino
    Now accepting new patients View Details
  • Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor

    The goal of this clinical trial is to learn whether providing teaching with a low-cost device can help to improve blood pressure, health outcomes, patient self-efficacy without exacerbating inequity between advantaged and disadvantaged patients.

    The main question\[s\] it aims to answer are:

    1. Does providing a free home blood pressure cuff improve control of hypertension?2. Does providing a free home blood pressure cuff have a greater impact on control of hypertension in disadvantaged populations?3. Does improved control of home blood pressure decrease adverse patient outcomes?

    Participants will be asked to

    * Take their blood pressure at home and records the results* Participate in follow-up phone calls from investigators at at 3 and 6 months

    Researchers will compare patients provided with home blood pressure monitors to those who are provided with routine education

    Investigator

    • Lironn Kraler, MD
    Now accepting new patients View Details
  • Study of Kidney Tumors in Younger Patients

    This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

    Investigators

    • Neyssa Marina
    • Jay Michael S. Balagtas
    Now accepting new patients View Details
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next

Dermatology Clinical Trials

  • Prostate Active Surveillance Study

    The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.

    Investigators

    • James D. Brooks
    • Harcharan Gill
    • Benjamin I. Chung
    Now accepting new patients View Details
  • Pediatric PET/MR Image Registry

    The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.

    Investigators

    • Kip E. Guja, MD PhD
    • Heike Daldrup-Link
    Now accepting new patients View Details
  • Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia

    Recent findings suggest that sleep disruption may contribute to the generation and maintenance of neuropsychiatric symptoms including anxiety, depression, agitation, irritation, and apathy while treating sleep disruption reduces these symptoms. Impairments in the neural systems that support emotion regulation may represent one causal mechanism mediating the relationship between sleep and emotional distress. However, this model has not yet been formally tested within a sample of individuals with or at risk for developing Alzheimer's Disease (AD)

    This proposal aims to test a mechanistic model in which sleep disturbance contributes to neuropsychiatric symptoms through impairments in fronto-limbic emotion regulation function in a sample of individuals at risk for developing, or at an early stage of AD.

    This study seeks to delineate the causal association between sleep disruption, fronto-limbic emotion regulation brain function, and neuropsychiatric symptoms. These aims will be achieved through a mechanistic, randomized 2-arm controlled trial design. 150 adults experiencing sleep disturbances and who also have cognitive impairment with the presence of at least mild neuropsychiatric symptoms will be randomized to receive either a sleep manipulation (Cognitive Behavioral Therapy for Insomnia CBT-I; n=75) or an active control (n=75). CBT-I improves sleep patterns through a combination of sleep restriction, stimulus control, mindfulness training, cognitive therapy targeting dysfunctional beliefs about sleep, and sleep hygiene education. Neuropsychiatric symptoms, fronto-limbic functioning, and sleep disruption will be assessed at baseline and at the end of the sleep manipulation through functional Magnetic Resonance Imaging (fMRI), clinical interviews, PSG recordings, and self-report questionnaires. Neuropsychiatric symptoms (anxiety and depression) and sleep disturbance (actigraphy, Insomnia Severity Index, and sleep diaries) will be assayed at baseline and each week throughout the sleep manipulation to assess week-to-week changes following an increasing number of CBT-I sessions. Wristwatch actigraphy will be acquired from baseline to the end of the sleep manipulation at week 11. Neuropsychiatric symptoms and sleep will be assessed again at six months post-manipulation.

    Investigator

    • Andrea Goldstein-Piekarski
    Now accepting new patients View Details
  • Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

    The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

    Investigators

    • Harlan Pinto
    • Billy W Loo, Jr, MD PhD FASTRO FACR
    • Quynh-Thu Le, MD, FACR, FASTRO
    • John B. Sunwoo, MD
    Now accepting new patients View Details
  • Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression

    The goal of this clinical trial is to compare ketamine to a placebo when given as a single infusion during IV sedation in adults with chronic pain and depression. We do not know whether ketamine will be more effective than placebo under these circumstances.

    This study aims to:

    * Evaluate whether placebo is non-inferior to ketamine in treating chronic pain and depression, when delivered under propofol sedation* Confirm that propofol sedation is a safe way to keep participants blinded to treatment* Assess patients' comfort with the sedation process to improve future studies* Explore whether patient expectations affects their pain and depression

    Participants will:

    * Need to qualify for the study based on stringent medical criteria* Undergo sedation with propofol* Randomly receive either a ketamine or a placebo (saline) infusion during sedation* Complete several study assessments over 5-7 weeks

    Investigator

    • Theresa Lii, M.D., M.S.
    Now accepting new patients View Details
  • Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

    This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

    Investigator

    • Natalie Shaubie Lui
    Now accepting new patients View Details
  • Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

    This is a protocol for prescreening of participants who would like to be in clinical studies in our Center at Stanford.

    Investigator

    • Sayantani Sindher
    Now accepting new patients View Details
  • Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

    Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.

    Now accepting new patients View Details
  • Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy.

    The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.

    Investigator

    • Jay Michael S. Balagtas
    Now accepting new patients View Details
  • Parent Intervention for Psychiatrically-Hospitalized Youth

    The purpose of the present study is to conduct a pilot randomized clinical trial (RCT) of a parent coaching intervention for parents of youth hospitalized for suicidal ideation, suicide attempt(s), or non-suicidal self-injury. Parents will receive either the parent coaching intervention (which includes safety planning and behavioral parenting skills training with a clinician and assistance with linkage to follow-up care by a case manager) or treatment as usual (TAU) for the inpatient unit. The long-term goal of the research is to determine if augmenting standard inpatient treatment with additional parenting intervention improves youth treatment response on suicide-related outcomes (i.e., suicidal ideation, non-suicidal self-injury, and suicide attempts). The goal of this pilot RCT is to collect preliminary data needed for a larger RCT, including feasibility, acceptability, safety, tolerability, engagement of the presumed mechanism of change (changes in parent emotions and behaviors), and signal detection of any changes in youth suicide-related outcomes.

    Investigator

    • Michele Berk, Ph.D.
    Now accepting new patients View Details
  • The GAstric Precancerous Conditions Study

    Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) are precancerous changes to the stomach mucosa which increases risk for subsequent gastric cancer.

    The Gastric Precancerous Conditions Study (GAPS) is an observational study of patients at elevated risk for gastric cancer. Investigators seek to recruit patients from endoscopy unit of Stanford Health Care, a large academic network of hospitals and clinics serving Northern California. Investigators will recruit patients who are both symptomatic (e.g. dyspepsia) and asymptomatic (e.g. referred for screening), and individuals both with known precursor lesions (such as intestinal metaplasia) or at high risk for carrying precursor lesions. A component of the study is long-term follow-up of individuals with gastric precursors. This is to understand their risk factors for histologic progression and regression. During both index and subsequent endoscopies, the study team will collect biospecimens (e.g. blood, saliva, gastric tissue).

    Investigators

    • Robert Huang
    • Joo Ha Hwang, MD, PhD
    Now accepting new patients View Details
  • Pediatric Prehospital Airway Resuscitation Trial

    This study is a Phase 3, multi-center, Bayesian Adaptive Sequential Platform Trial testing the effectiveness of different prehospital airway management strategies in the care of critically ill children. Emergency Medical Services (EMS) agencies affiliated with the Pediatric Emergency Care Applied Research Network (PECARN) will participate in the trial. The study interventions are strategies of prehospital airway management: \[BVM-only\], \[BVM followed by SGA\] and \[BVM followed by ETI\]. The primary outcome is 30-day ICU-free survival. The trial will be organized and executed in two successive stages. In Stage I of the trial, EMS personnel will alternate between two strategies: \[BVM-only\] or \[BVM followed by SGA\]. The \[winner of Stage I\] will advance to Stage II based upon results of Bayesian interim analyses. In Stage II of the trial, EMS personnel will alternate between \[BVM followed by ETI\] vs. \[Winner of Stage I\].

    Investigator

    • Manish I. Shah, MD, MS
    Now accepting new patients View Details
  • Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

    The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.

    Investigator

    • David Epstein
    Now accepting new patients View Details
  • Roadmap to Parenthood: Testing the Efficacy of a Decision Aid and Planning Tool for Family Building After Cancer

    This study will test a decision support intervention that consists of a web-based 'decision aid and planning tool' for family building after cancer in a randomized controlled trial.

    Investigator

    • Catherine Benedict, PhD
    Now accepting new patients View Details
  • SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

    SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

    The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of continuing on treatment for \>24 weeks.

    Investigator

    • Joyce Teng, MD, PhD
    Now accepting new patients View Details
  • Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

    The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.

    Now accepting new patients View Details
  • Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility

    The aims of this protocol are: to collect and store diseased and normal tissue and body fluid samples from new and returning patients at St. Jude Children's Research Hospital (SJCRH), affiliated sites and collaborating institutions; to collect and store samples from relatives of SJCRH patients; to collect and store retrospective and prospective pertinent corresponding clinical and laboratory data on disease characterization, treatment, and outcome; and to serve as a source of human biological samples and corresponding laboratory and clinical data.

    Investigator

    • Norman J. Lacayo, MD
    Now accepting new patients View Details
  • Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation

    The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.

    Investigator

    • Alexander C. Perino
    Now accepting new patients View Details
  • Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor

    The goal of this clinical trial is to learn whether providing teaching with a low-cost device can help to improve blood pressure, health outcomes, patient self-efficacy without exacerbating inequity between advantaged and disadvantaged patients.

    The main question\[s\] it aims to answer are:

    1. Does providing a free home blood pressure cuff improve control of hypertension?2. Does providing a free home blood pressure cuff have a greater impact on control of hypertension in disadvantaged populations?3. Does improved control of home blood pressure decrease adverse patient outcomes?

    Participants will be asked to

    * Take their blood pressure at home and records the results* Participate in follow-up phone calls from investigators at at 3 and 6 months

    Researchers will compare patients provided with home blood pressure monitors to those who are provided with routine education

    Investigator

    • Lironn Kraler, MD
    Now accepting new patients View Details
  • Study of Kidney Tumors in Younger Patients

    This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

    Investigators

    • Neyssa Marina
    • Jay Michael S. Balagtas
    Now accepting new patients View Details
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next

Pediatric Dermatology Clinical Trials

No trials match your search ""

No trials match your search ""

No trials match your search ""

On this page

On this page

Ongoing & Upcoming Studies

Ongoing Studies

Upcoming Studies

Dermatology

Stanford Medicine

News

Careers

Contact

Health Care

Stanford Health Care

Stanford Children's Health

Stanford School of Medicine

About

Contact

Maps & Directions

Careers

Basic Science Departments

Clinical Science Departments

Academic Programs

Vision

Find People
Visit Stanford
Search Clinical Trials
Give a Gift
©2025 Stanford University
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • See us on Facebook
  • See us on X (Twitter)
  • Stanford University
  • Stanford School of Medicine
  • Stanford Health Care
  • Stanford Children's Health
  • Stanford Health Care Tri-Valley
  • Stanford Medicine Partners